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Abstract. Endometrial carcinoma is the most common gynaeco-
logical malignancy. There is however a lack of curative therapies, 
especially for patients diagnosed with late stage, recurrent or 
aggressive disease, who have a poor prognosis. Interleukin 
(IL) 11 is a pleiotropic cytokine that has a role in a number of 
cancers including colon and breast cancer. IL11 was recently 
found to be upregulated in endometrial cancers, however the 
function of IL11 in endometrial cancer is not known. This study 
aimed to determine the effects of IL11 on endometrial cancer 
cell proliferation, adhesion and migration. Three endometrial 
cancer cell lines, Ishikawa, HEC-1A and AN3CA (derived from 
endometrial cancers grade I, II and III, respectively), were used to 
determine the effect of IL11 on endometrial cancer cell function. 
Cell proliferation and viability were assessed by BrdU and Wst-1 
assays. Cell adhesion to the extracellular matrix proteins fibro-
nectin, collagen I and IV, vitronectin and laminin was assessed. 
Modified boyden chambers were utilized to access IL11 action 
on migration and invasion, respectively. The specific effect of 
IL11 action on these processes was determined using a unique 
IL11 inhibitor. IL11 phosphorylated (p)-STAT3 protein abun-
dance in all 3 cell lines but had no effect on pERK and pAKT 
abundance. Similarly, IL11 had no effect on cell proliferation and 
viability but increased adhesion of ANC3A cells to fibronectin 
while having no effect on the other extracellular matrix proteins. 
IL11 did not alter the adhesive properties of the Ishikawa and 
HEC-1A cells. In the AN3CA cells, IL11 treatment resulted in 
a 50% increase in migration and co-treatment with the specific 
IL11 inhibitor or a STAT3 inhibitor abolished the effect. This 
study shows a role for IL11 in endometrial cancer and suggests 
IL11 may be involved in endometrial cancer development and 
thus may be useful as a therapeutic target.
Introduction
Endometrial carcinoma (EC) is the most common gynaeco-
logical malignancy in the Western world (1). The rate is rising 
in developed countries, most likely due to the rise in obesity and 
increased life expectancies (2).
EC can be classified into two groups (3): type I lesions develop 
from excess unopposed estrogen stimulation of the endometrium, 
causing hyperplasia, which may progress to malignancy. These 
cancers typically occur in younger, pre-menopausal women, are 
diagnosed earlier and have a good prognosis. Type II tumours 
are estrogen independent. They commonly occur in older, 
post-menopausal women, are diagnosed much later than type I 
tumours and are usually more aggressive histological subtypes 
(clear cell or serous carcinoma). These high grade tumours have 
frequently already undergone extensive invasion of surrounding 
structures or lymph node or distant metastases, hence have a 
very poor prognosis.
Unfortunately, there is currently no appropriate screening 
test available for EC. The main treatment strategy is surgical, 
involving a total abdominal hysterectomy and bilateral 
salpingo-oophorectomy. There is a lack of curative therapies 
for patients diagnosed with late stage, recurrent or aggressive 
disease. Adjuvant chemotherapy or radiotherapy is used for 
patients with advanced disease (4). Hormonal treatment with 
progestins are used clinically, but response is restricted to those 
with hormone receptor-positive tumours, and recurrence rate is 
high (5). Therefore, the identification of novel factors involved 
in cancer progression is important in the development of new 
pharmacological therapies to improve EC prognosis.
Interleukin (IL) 11 is a member of the IL6 family of cyto-
kines. It signals via the IL11 receptor (R) α and gp130 receptor 
complex to activate the Janus tyrosine kinases (JAK). This, in 
turn, can induce the activation of three independent downstream 
signalling pathways: the signal transducer and activator of tran-
scription (STAT) pathway, the Ras-mitogen activated protein 
kinase (MAPK) pathway; and the phosphotidylinositol-3 kinase 
(PI-3K) pathway (6). In the human endometrium, IL11 primarily 
acts via STAT3 (7). IL11 is a critical factor in the establish-
ment of pregnancy and is associated with several pathologies 
of pregnancy (8-10). Moreover, current studies have found a 
role for IL11 in trophoblast migration and invasion (11,12), 
processes that are similar to that of cancer progression. While 
both trophoblast invasion and cancer cell invasion are similar, 
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trophoblast invasion is a highly controlled process unlike that of 
cancer cell invasion.
Studies have reported a role for IL11 in several epithelial 
cancers, including breast (13), gastric (14) and colorectal 
cancer (15). ECs show elevated levels of IL11 and IL11Rα mRNA 
compared to normal proliferative phase endometrium (16). 
Furthermore, we have demonstrated that IL11 protein is upregu-
lated in EC tissue and uterine lavage fluid, compared to control 
post-menopausal endometrial tissue and lavage fluid respec-
tively (17). Whilst this evidence shows that IL11 is produced 
by EC, its function in EC is not yet known. In this study, we 
investigated the effects of IL11 on proliferation, adhesion and 
migration in endometrial cancer cell lines. We also investigated 
the effects of IL11 inhibition on these actions.
Materials and methods
Materials. Human recombinant IL11 was obtained from R&D 
Systems (Sydney, Australia) and diluted in 0.1% bovine serum 
albumin (BSA) in phosphate-buffered saline (PBS). STAT3 
phosphorylation inhibitor (STAT3i; 20 µM; Calbiochem, 
San Diego, CA, USA). PEGylated IL11 inhibitor (IL11 inhibitor) 
was produced by CSL Limited (Melbourne, Australia) (18,19).
Cell lines. Three endometrial cancer cell lines were used: 
Ishikawa, HEC-1A and AN3CA cells, which are derived from 
grade I, II and III EC, respectively (20-22). The cell lines were 
cultured in DMEM, McCoy's or MEM (Invitrogen, Melbourne, 
Australia) respectively and supplemented with 10% fetal 
bovine serum (FBS; SAFC Biosciences, Lenexa, KS, USA), 
1% L-glutamine (Invitrogen) and 1% penicillin-streptomycin 
(Invitrogen).
SDS-PAGE and western blot analysis. Confluent cells were 
serum starved for 24 h before treatment with control, IL11 
(100 ng/ml, concentration chosen from previous studies and 
concentration-response studies) (11) for 10, 30 or 60 min. Cell 
lysates were collected using lysis buffer [50 mM Tris-Base, 
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, and 
25 mM B glycerolphosphate (pH 7.5)] containing protease inhib-
itor (2 µl/ml; ThermoScientific, Waltham, MA, USA). Cell lysate 
(20 µg) was loaded and electrophoresed on a 10% SDS-PAGE 
gel. The protein was transferred to polyvinylidene fluoride 
(PVDF) membranes before it was incubated with phosphory-
lated (p)-STAT3 (Tyr705) (no. 9131), total STAT3 (no. 9132), 
phosphorylated (p)-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(no. 4370), total p44/42 MAPK (Erk1/2) (no. 4695) phosphory-
lated (p)-AKT (Ser473) (no. 4058) and total AKT (pan) (no. 4691) 
(Cell Signaling Technology, Danvers, MA, USA) primary 
antibodies overnight at 4˚C. Membranes were incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibody 
(50 µg/l; DakoCytomation) and HRP activity visualized using 
the enhanced chemiluminescence system (ThermoScientific). 
Membranes were exposed to film and developed, and the relative 
band intensity determined using densitometric analysis (ImageJ 
v1.43, National Institutes of Health, Bethesda, MD, USA).
Enzyme-linked immunoassays (ELISAs). Phosphorylated 
(p)-STAT3 and total STAT3 were measured using an established 
sandwich-ELISA (Cell Signaling Technology) according to 
manufacturer's protocol. Prior to assay, confluent cells were serum 
starved for 24 h before treatment with control, IL11 (100 ng/ml) 
+ PEGylated IL11 inhibitor (IL11 inhibitor; 10 µg/ml) or IL11 
inhibitor alone (10 g/ml). Cell lysates were collected using lysis 
buffer [50 mM Tris-Base, 150 mM NaCl, 2 mM EDTA, 2 mM 
EGTA, 25 mM NaF, and 25 mM B glycerolphosphate (pH 7.5)] 
containing protease inhibitors (2 µl/ml; ThermoScientific).
Briefly, a 96-well plate was incubated overnight at 4˚C 
with capture antibody. The plate was washed and blocked with 
blocking buffer (1X PBS, 0.05% Tween-20, 1% BSA) for 1 h 
at 37˚C. The plate was washed four times and then incubated 
with 30 µg of protein lysates per well for 2 h at 37˚C. A further 
wash was required followed by incubation with detection 
antibody for 1 h at 37˚C. Following this, the plate was washed 
and secondary antibody was applied for 30 min at 37˚C before 
measuring the absorbance at 450 nm with a Wallac Envision 
2103 plate reader (Perkin Elmer).
Bromodeoxyuridine (BrdU) assay. BrdU ELISA kit (Roche 
Applied Science, Indianapolis, IN, USA) was used to assess 
cell proliferation as per the manufacturer's instructions and as 
previously described (12). Briefly, cells were seeded into 96-well 
plates (5,000 cells/well) and allowed to adhere for 8 h. They 
were then serum starved for 24 h before treatment with control, 
IL11 [100 ng/ml + IL11 inhibitor (10 µg/ml)] for 48 h at 37˚C. 
BrdU (10 mM) was added to each well and incubated for 2 h 
at 37°C. BrdU incorporation was measured at 450 nm with a 
Wallac Envision 2103 plate reader (Perkin Elmer).
WST-1 assay. A Wst-1 assay was used to determine the 
effect of IL11 on cell viability as previously described (12). 
Cells were seeded into 96-well plates (10,000 cells/well) and 
allowed to adhere for 8 h. Cells were then serum starved for 
24 h before treatment with control, IL11 [100 + IL11 inhibitor 
(10 µg/ml) ng/ml] for 48 h at 37˚C. Wst-1 dye (1:10; Roche 
Applied Science) was then added to each well and incubated 
for 4 h at 37˚C. The viable cell number was determined by 
measuring the absorbance at 450 nm with a Wallac Envision 
2103 plate reader (Perkin Elmer).
Adhesion assay. To determine the effect of IL11 on cell adhesion, 
CytoMatrix cell adhesion strips (Millipore, Sydney, Australia) 
coated with extracellular matrix (ECM) proteins (fibronectin, 
laminin, collagen I, collagen IV and vitronectin) were used 
according to the manufacturer's instructions. Briefly, cells were 
serum starved for 24 h, then treated with IL11 [100 or 100 + IL11 
inhibitor (10 µg/ml)]. Cells were seeded [50,000 (Ishikawa and 
HEC-1A) or 60,000 (AN3CA)] into the wells and incubated for 
2 h at 37˚C. Non-adherent cells were washed off and adherent 
cells stained with 0.2% crystal violet in 50% ethanol solution. 
The stain was eluted with solubilisation buffer (1:1 solution of 
NaH2PO4 and 50% ethanol) and absorbance was read at 560 nm 
with a Wallac Envision 2103 plate reader (Perkin Elmer).
Migration assay. Chemotaxis cell (96-well) migration kits 
(Millipore) were used according to the manufacturer's instruc-
tions to assess chemotactic cell migration. Briefly, 50,000 cells 
in 1% FBS were seeded into each of the upper wells. Cells were 
pre-treated with the STAT-3 inhibitor (10 µM) for 18 h prior to 
the migration assay (11,23). Control, IL11 [(100 ng/ml) or IL11 
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(100 ng/ml) + IL11 inhibitor (10 µg/ml)] was added to the lower 
wells and cells were incubated for 24 h at 37°C. A positive control 
consisting of 10% FCS was added to the lower chamber as previ-
ously described (12). Migrated cells were detached, lysed and 
quantified with a dye by measuring the fluorescence at 485/535 
with a Wallac Envision 2103 plate reader (Perkin Elmer).
Statistical analysis. All data are expressed as mean ± standard 
error of the mean (SEM) fold change in comparison to control 
for graphical representation. Raw data were analysed using 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) 
for Windows. The raw data were tested for normal distribution 
and the appropriate statistical test utilized as described below. 
All functional assays had a minimum of 3 independent experi-
ments in triplicate wells, unless otherwise stated. Normally 
distributed data were analysed statistically by one-way analysis 
of variance for three or more groups or a paired t-test was 
used to analyse differences between two groups. Not normally 
distributed data were analysed by Mann-Whitney (comparison 
of two groups) or Kruskal-Wallis (comparison of three of more 
groups) tests. A p-value of <0.05 was considered statistically 
significantly different between groups.
Results
IL11 signals via STAT3 in endometrial cancer cell lines. We 
examined the effect of IL11 on three downstream intracellular 
pathways. IL11 (100 ng/ml) phosphorylated (p)-STAT3 in all 
three cell lines after 10 min (Fig. 1A) and had no effect on 
STAT3 protein abundance. Moreover, a sandwich-ELISA, used 
for quantitative STAT3 phosphorylation analysis in the AN3CA 
cells, demonstrated that IL11 (100 ng/ml) significantly upregu-
lated (p)-STAT3 compared to control and this was reversed by 
co-treatment with the IL11 inhibitor (Fig. 1B). Treatment of 
ANC3A cells with IL11 inhibitor alone or IL11 at a concentra-
tion of 1 ng/ml did not alter (p)-STAT3 compared to control. As 
IL11 is known to activate a number of other signalling pathways 
in cancer cells we investigated whether IL11 altered the MAPK 
or PI3K pathways. We demonstrated that IL11 did not activate/
enhance the MAPK or PI3K signalling pathways in Ishikawa, 
HEC-IA and ANC3A cells [Fig. 1C (i) and (ii)].
IL11 had no effect on cell proliferation or viability. To deter-
mine the effect of IL11 on cell proliferation and cell viability, 
BrdU and Wst-1 assays were used, respectively. IL11 (100 ng/
ml) or IL11 (100 ng/ml) + IL11 inhibitor (10 µg/ml) had no 
significant effect on cell proliferation (BrdU; Fig. 2A) or cell 
viability (Wst-1; Fig. 2B) in the three cell lines. IL11 inhibitor 
alone did not affect cell proliferation (data not shown).
IL11 alters endometrial cancer cell adhesion. Using the three 
different cell lines Ishikawa, HEC-1A and AN3CA (as models 
of grade I, II and III, respectively) we investigated the effects 
of IL11 on EC cell adhesion to ECM proteins. AN3CA cells 
showed maximal binding to fibronectin, laminin and vitronectin 
but no binding to both collagen I and IV (Fig. 3A). AN3CA cells 
treated with IL11 (100 ng/ml) increased binding to fibronectin 
(P<0.05); Fig. 3B) compared to control. Co-culture of AN3CA 
cells with IL11 (100 ng/ml) and IL11 inhibitor or STAT3 inhib-
itor significantly decreased adhesion to fibronectin compared 
Figure 1. IL11 signals via phosphorylated STAT3 in AN3CA, Ishikawa and 
HEC-1A cells. (A) Cells were cultured with IL11 (100 ng/ml) and the abun-
dance of phosphorylated (p) STAT3 and STAT3 was determined after 10, 
30 and 60 min. Data are representative of n=3 experiments. (B) pSTAT3 
ELISA assay: ANC3A cells were treated with control, IL11 [1, 100, 100 ng/
ml + PEGylated IL11 inhibitor (IL11 inhibitor; 10 µg/ml) and IL11 inhibitor 
(10 µg/ml) alone] for 10 min. Data are expressed as mean (expressed as fold 
change from control) ± SEM and represents triplicate treatments from n=3 
individual experiments. *P<0.05; IL11 (100 ng/ml) compared to all other 
groups. (C) Effect of IL11 on ERK and AKT phosphorylation in Ishikawa, 
HEC-1A and AN3CA cells. Cells were cultured with control, IL11 (100 ng/ml) 
for 10, 30 and 60 min. Following western blot analysis protein bands for pERK 
(42, 44 kDa), total ERK (42, 44 kDa), p-Ser473-AKT (60 kDa) and total AKT 
(60 kDa) were detected. Data are representative of two independent experi-
ments assayed in triplicate.
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to cells treated with IL11 (100 ng/ml) (Fig. 3B). Treatment of 
Ishikawa and HEC-1A cells with IL11 (100 ng/ml) did not 
significantly alter cell adhesion to the ECM (data not shown).
IL11 regulates ANC3A cell migration via STAT3. The effect of 
IL11 on cell migration was examined in ANC3A, Ishikawa 
and HEC-1A cells (Fig. 4). AN3CA cells treated with IL11 
(100 ng/ml) resulted in a 50% increase in cell migration 
compared to control (P<0.05; Fig. 4). This effect was reversed 
by co-incubation with IL11 (100 ng/ml) and the IL11 specific 
inhibitor (10 µg/ml) (Fig. 4). Similarly, ANC3A cells co-incu-
bated with IL11 and the STAT3 inhibitor reduced cell migration 
compared to cells treated with IL11 alone. By contrast, IL11 
had no effect on Ishikawa and HEC-1A cell migration (Fig. 4).
Discussion
This study investigated the effect of IL11 in endometrial cancer 
cell function – proliferation, viability, adhesion and migration 
using three human endometrial carcinoma cell lines (Ishikawa, 
HEC-1A and AN3CA). We demonstrated that IL11 increased 
cell adhesion of ANC3A cells to fibronectin but did not affect 
Ishikawa and HEC-1A cell adhesive properties. IL11 had 
no effect on cell proliferation or viability. By contrast, IL11 
increased AN3CA cell migration while it did not significantly 
alter Ishikawa or HEC-1A cell migration. A unique IL11 
inhibitor reversed the observed effects on both cell adhesion 
and migration. Similarly, a STAT3 inhibitor blocked the IL11 
mediated effects on ANC3A cell adhesion suggesting IL11 
regulated these processes via (p)-STAT3. In agreement, IL11 
Figure 2. IL11 does not alter viability or proliferation of AN3CA, Ishikawa and 
HEC-1A cells. Cell proliferation and cell viability were assessed by BrdU and 
by Wst-1 assays respectively as detailed in Materials and methods. Cells were 
treated with control, IL11 (100 ng/ml IL11) and IL11 (100 ng/ml) + IL11 inhib-
itor (10 µg/ml) and cell proliferation and viability assessed. Data are expressed 
as mean (expressed as fold change from control) ± SEM and represents triplicate 
treatments from n=5 independent experiments.
Figure 3. Effect of IL11 on ANC3A cell adhesion to extracellular matrix 
proteins. (A) Cell adhesion to collagen I (COL-1), collagen IV (COL-IV), fibro-
nectin (FN) and vitronectin (VN) and laminin (LN) was determined using 
Cytomatrix Cell adhesion assays as detailed in the Materials and methods. 
(B) Cells were pre-treated with combinations of control, IL11 (100 ng/ml), IL11 
inhibitor (10 µg/ml), STAT3 inhibitor (20 µM) for 24 h prior to the adhesion 
assays. Cells were then transfered to FN coated plates for 90 min for measure-
ment of cell adhesion to FN. Data are expressed as mean ± SEM and represents 
triplicate treatments from n=5 (inhibitor studies; n=3) individual experiments. 
*P<0.05 compared to control or between groups as indicated.
Figure 4. Effect of IL11 on AN3CA, Ishikawa and HEC-1A cell migration. 
Cells were treated with control, IL11 (100 ng/ml) and IL11 (100 ng/ml) + 
IL11 inhibitor (10 µg/ml) for 24 h and then assessed. Data are expressed as 
mean (expressed as fold change from control) ± SEM and represents triplicate 
treatments from n=3 individual experiments. *P<0.05 compared to control or 
between groups as shown.
INTERNATIONAL JOURNAL OF ONCOLOGY  41:  759-764,  2012 763
phosphorylated (p)-STAT3 and did not affect the MAPK or 
PI3K pathways in the Ishikawa, HEC-1A and AN3CA cells.
IL11 signalling is initiated via the IL11Rα and the gp130 
receptor complex (24). In the endometrium, IL11 primarily 
signals via the JAK/STAT intracellular pathway (25). This is 
also the case in endometrial cancer cells as demonstrated in 
the present study. JAK/STAT signalling has been well studied 
in other cancers (26), including breast cancer, pancreatic, 
colorectal, prostate and head and neck cancer as well as 
leukaemia and lymphoma (27). Evidence shows that inap-
propriate STAT activation results in an environment that is 
conducive to tumour development, such as inhibition of apop-
tosis, promotion of angiogenesis and proliferation (28). For 
instance, IL11 signals via STAT3 to increase tumourigenesis 
in gastric cancer, as demonstrated with a gp130 Y757 knock-in 
mutant mouse model (14). In the present study we demon-
strated that blocking the IL11 pathway inhibited adhesion and 
migration of the ANC3A cells that were derived from grade III 
(undifferentiated) tumours via the activation of STAT3.
IL11 had no effect on cell proliferation or viability in all 
three cancer cell lines tested. This finding is consistent with 
the lack of effect of IL11 on proliferation of human trophoblast 
cells (12), lung and colon cancers (29). It is well known that IL11 
has an anti-apoptotic effect under stressful conditions. In the 
gastrointestinal system, IL11 protects against mucosal injury 
in diseases such as inflammatory bowel disease, intestinal isch-
emia, necrotising enterocolitis and irradiation. However, from 
our data, it is unlikely that IL11 prevents apoptosis due to the 
lack of effect on cell proliferation and cell viability.
We demonstrated that IL11 significantly altered ANC3A 
cell adhesion to fibronectin, while no significant effect was seen 
with the other extracellular matrix proteins tested and further-
more no effect on Ishikawa and HEC-1A cell adhesion was 
detected. By comparison we previously demonstrated that IL11 
stimulated cell adhesion of human endometrial epithelial cells 
to fibronectin and collagen IV, as well as primary trophoblast 
cells (30). Integrins are likely candidates by which cells regulate 
adhesion (22). Whether IL11 regulates integrins in endometrial 
cancer cells, however, remains to be determined. Tumours 
of higher grades are more likely to be less adhesive, lending 
themselves to a more migratory phenotype. This has been found 
in pancreatic (31) and prostate cancer (32). Paradoxically, the 
present study demonstrated IL11 increased ANC3A cell adhe-
sion to fibronectin and migration. Cell migration involves the 
adhesion and de-adhesion of cells and our data suggest there 
may be mechanisms additional to cell adhesion by which IL11 
facilitated ANC3A cell migration. A recent study reported, that 
fibronectin gene expression is reduced in endometrial cancer 
tissue compared to normal endometrium and suggest that fibro-
nectin may be useful as a marker of disease progression (33).
IL11 increased migration of ANC3A cells via (p)-STAT3 
while no effect was seen with IL11 on Ishikawa and HEC-1A 
cell migration. IL11 maximally activated (p)-STAT3 in the 
ANC3A cells compared to the Ishikawa and HEC-1A cells 
suggesting that IL11 was less responsive to the latter two cell 
lines. Interestingly, Ishikawa and HEC-1A cells are derived 
from grade I and II endometrial cancers, while ANC3A cell are 
derived from grade III cancers suggesting that IL11 has a role 
primarily in the migratory higher grade tumours. Similarly, IL11 
has previously been demonstrated to stimulate the migration of 
EVT-hybridoma cells (12) and outgrowth of primary extravil-
lous trophoblast cells (23). In other cancers such as colorectal 
cancer, IL11 increases cell migration via the PI3K pathway and 
inhibiting this pathway reverses the effect (15). Similarly IL11 
stimulates migration in other cells, including breast cancer cell 
lines (34) and endothelial progenitor cells (35).
A number of studies demonstrate that IL11 increases 
the invasive capacity of many other cancers. IL11 increases 
invasion of JEG3 choriocarcinoma cells (36), squamous cell 
carcinomas (29) and breast cancer cells (37). In gastric cancer, 
IL11 promotes cellular invasion via the STAT3 pathway (14). 
Similarly, in colorectal cancer, IL11 levels are associated with 
the extent of tumour invasion and infiltration into vessels (15). 
In conclusion, these results demonstrate a role for IL11 in 
endometrial carcinoma cells likely acting via (p)-STAT3. IL11 
is upregulated in grade I tumours and in uterine lavage fluid (17) 
suggesting IL11 may be useful as a marker for endometrial 
cancer. This study supports a role for IL11 in endometrial 
cancer progression and in vivo studies are required to determine 
whether targeting IL11 may be useful as a treatment option for 
endometrial cancer progression.
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